Harpoon Therapeutics Presents Preclinical Results for Novel

Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor... | June 19, 2023

Related Keywords

United States , American , Luke Walker , Roberth Uhl , Banmeet Anand , Drug Administration , Exchange Commission , American Association For Cancer Research , Harpoon Therapeutics Inc , Nasdaq , American Association , Cancer Research , Annual Meeting , Activating Construct , Senior Vice President , Translational Medicine , Chief Medical Officer , Harpoon Therapeutics , Fast Track , Orphan Drug Designation , Private Securities Litigation Reform Act , Harpoon Therapeutic ,